MMP2 and inflammatory breast carcinoma: In this study, our objective was to evaluate the prognostic impact of MMP2 and MMP9 serum levels, at baseline and during treatment, in patients with IBC treated with neoadjuvant bevacizumab, trastuzumab and chemotherapy.